Sai Life Sciences releases its first Integrated Report for FY 2025–26

Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), has released its first Integrated Report for FY 2025–26. Building on six consecutive years of sustainability reporting, the report marks an important milestone in the company’s reporting journey, bringing together financial and non-financial performance to provide a comprehensive view of its strategy, business performance, sustainability priorities, and long-term value creation.

The report has been prepared with reference to the International Integrated Reporting Council (IIRC) Framework and the Global Reporting Initiative (GRI) Standards. You can read it here: Sai-Life-Sciences-AR-26.pdf

Commenting on the release, Krishna Kanumuri, Managing Director and CEO, Sai Life Sciences, said: “Building Sai Life Sciences for the long term requires us to look beyond individual measures of performance and understand how science, capabilities, people, partnerships, and responsible business practices come together to create lasting value. Our first Integrated Report brings these dimensions together, reflecting the progress we have made, the capabilities we are building, and our priorities for the years ahead.”

Key Highlights

The report highlights key milestones across Sai Life Sciences’ sustainability and responsible business practices:

• EcoVadis Platinum rating, placing Sai Life Sciences among the top 1% of companies assessed globally.
• Bidar manufacturing facility powered by 100% renewable electricity.
• Platinum-level Zero Waste to Landfill certification from TÜV India Private Limited for Unit 2 (Hyderabad) and Unit 4 (Bidar), with waste diversion rates of 95.92% and 99.43%, respectively, in FY 2025–26.
• SA8000 certification, reinforcing the company’s commitment to social accountability and responsible employment practices.

Reporting Across the Six Capitals

The report adopts the Six Capitals framework to provide a connected view of the company’s performance and long-term value creation.

1. Financial Capital: During FY 2025–26, Sai Life Sciences invested ₹633 crore in capital expenditure to strengthen its scientific capabilities, manufacturing infrastructure, and operational capacity. The company plans to invest ₹1,100–1,300 crore in FY 2026–27, its largest investment program to date, focusing on capacity expansion, capability development, technology, and artificial intelligence (AI).

2. Manufactured Capital: During FY 2025–26, the company advanced manufacturing capacity expansion projects, including additional production blocks, and progressed development of its new manufacturing site at Choutuppal. Planned across approximately 40 acres, the facility is designed to accommodate around 1,400 KL of reactor capacity. The company also strengthened its advanced manufacturing capabilities through technologies including flow chemistry, continuous extraction and distillation, plug-flow reactors and crystallization, tangential flow filtration, short-path distillation, and wet milling.

3. Intellectual Capital: Sai Life Sciences continued to strengthen its scientific capabilities across emerging therapeutic areas and complex modalities, supported by a team of 2,600+ scientists. The company expanded its use of advanced preclinical models, including organoids and spheroids, to support more predictive efficacy and toxicity assessments.  

4. Human Capital: With 5,224 employees, Sai Life Sciences continued to focus on workforce development, employee engagement, and inclusion across its research, development, and manufacturing operations. During FY 2025–26, women represented 15% of its workforce, while employee retention stood at 88%. The company’s SA8000 certification reinforced its commitment to labor rights, workplace safety, ethical employment practices, and employee well-being.

5. Social and Relationship Capital: Sai Life Sciences strengthened supplier governance and integrated environmental, social, and governance (ESG) considerations further into procurement during FY 2025–26. The company also deepened collaboration with strategic partners to support a more transparent and responsible supply chain. Its ISO 28000:2022 certification reinforces a structured approach to supply chain security and risk management.

6. Natural Capital: Environmental stewardship remained an important focus across Sai Life Sciences’ research, development, and manufacturing operations. During FY 2025–26, the company advanced initiatives spanning renewable energy, decarbonization, water stewardship, waste management, and resource efficiency. It also continued to implement its FY 2025–30 Water Neutrality Strategy, supporting its approach to responsible water management and long-term operational resilience.

Through its first Integrated Report, Sai Life Sciences brings together its financial, operational, scientific, social, and environmental performance in a unified account of its progress and priorities. The report reflects the company’s commitment to transparent reporting, responsible growth, and long-term value creation.